medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-10-37-41medsovet-3051Research ArticleТАРГЕТНАЯ ТЕРАПИЯ ОПУХОЛЕЙTarget therapy of tumorsЦеритиниб в лечении ALK-позитивных больных немелкоклеточным раком легкогоCeritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancerЛактионовК. К.LaktionovK. K.

д.м.н., заместитель директора по лечебной работе Научно-исследовательского института клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации, и.о. зав. хирургическим отделением №13 (клинических биотехнологий) торако-абдоминального отдела Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Dr. of Sci. (Med.), Deputy Director of Clinical Care, Trapeznikov Research Institute of Clinical Oncology, Federal State Budgetary Institution «Blokhin National Medical Cancer Research Center» of the Ministry of Health of the Russian Federation, Acting Head of Surgical Unit No. 13 (Clinical Biotechnology), Thoraco-Abdominal Department, Federal State Budgetary Institution «Blokhin National Medical Cancer Research Center» of the Ministry of Health of the Russian Federation.

РеутоваЕ. В.ReutovaE. V.

к.м.н., старший научный сотрудник хирургического отделения №13 (клинических биотехнологий) Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med.), Senior Researcher, Surgical Unit No. 13 (Clinical Biotechnology), Federal State Budgetary Institution «Blokhin National Medical Cancer Research Center» of the Ministry of Health of the Russian Federation.

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.РоссияFederal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.Russian Federation2019220620190103741Copyright © Лактионов К.К., Реутова Е.В., 20192019Лактионов К.К., Реутова Е.В.Laktionov K.K., Reutova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3051

Церитиниб стал вторым после кризотиниба ингибитором тирозинкиназы ALK, зарегистрированным в РФ для лечения ALK- позитивных больных немелкоклеточным раком легкого (НМРЛ). Позднее в РФ был зарегистрирован другой ингибитор ALK 2-го поколения – алектиниб. Таким образом, в российской клинической практике появилась возможность, во-первых, для продолжения таргетной терапии препаратами второго поколения после прогрессирования на кризотинибе, во-вторых, для назначения более активных препаратов в первую линию, обеспечивая наилучшие результаты лечения.

Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with non-small cell lung cancer (NSCLC). Later alectinib was registered. Thus, we have the opportunity, firstly, to continue targeted therapy with second-generation drugs after progression on crizotinib, and secondly, the appointment of more active drugs in the first line provides the best results of treatment.

ALKнемелкоклеточный рак легкогоцеритинибALKnon-small-cell lung cancerceritinibReferencesКлинические рекомендации АОР по терапии рака легкого http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf. [AOR clinical guidelines for the lung cancer treatment http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf.] (In Russ).Клинические рекомендации АОР по терапии рака легкого http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf. [AOR clinical guidelines for the lung cancer treatment http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf.] (In Russ).Santarpia M., Daffinà M.G., D’Aveni A. et al. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Design, Development and Therapy, 2017.Santarpia M., Daffinà M.G., D’Aveni A. et al. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Design, Development and Therapy, 2017.Kim D.W., Mehra R., Tan D.S.W. et al. Activity and safety of ceritinib in patients with ALKrearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452-463.Kim D.W., Mehra R., Tan D.S.W. et al. Activity and safety of ceritinib in patients with ALKrearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452-463.Preusser M., Winkler F., Valiente M., et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262. doi:10.1136/esmoopen-2017-000262.Preusser M., Winkler F., Valiente M., et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262. doi:10.1136/esmoopen-2017-000262.Katayama R., Khan T.M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535-7540.Katayama R., Khan T.M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535-7540.Friboulet L., Li N., Katayama R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 June;4(6):662–673.Friboulet L., Li N., Katayama R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 June;4(6):662–673.Felip E., Nishio M., Orlov S. et al. Phase II study of ceritinib in ALK inhibitor (ALKi)- naïve patients with ALK-rearranged nonsmall cell lung cancer: final efficacy and safety results from ASCEND-3. ESMO. 2018;abstract LBA57.Felip E., Nishio M., Orlov S. et al. Phase II study of ceritinib in ALK inhibitor (ALKi)- naïve patients with ALK-rearranged nonsmall cell lung cancer: final efficacy and safety results from ASCEND-3. ESMO. 2018;abstract LBA57.Felip E., Orlov S., Park K. et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK +) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27(suppl 6):416-454.Felip E., Orlov S., Park K. et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK +) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27(suppl 6):416-454.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinibindication-previously-untreated-alk-positivemetastatic-nsclc.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinibindication-previously-untreated-alk-positivemetastatic-nsclc.Soria J.C., Tan D.S., Chiari R., et al: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, openlabel, phase 3 study. Lancet. 2017;389:917-929.Soria J.C., Tan D.S., Chiari R., et al: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, openlabel, phase 3 study. Lancet. 2017;389:917-929.Shaw A.T., Kim T.M., Crinò L. et al. ASCEND-5: a randomised, phase 3 study of ceritinib versus chemotherapy in adult patients with ALKrearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib. Lancet Oncol. 2017;18:874–886.Shaw A.T., Kim T.M., Crinò L. et al. ASCEND-5: a randomised, phase 3 study of ceritinib versus chemotherapy in adult patients with ALKrearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib. Lancet Oncol. 2017;18:874–886.GLEEVEC (imatinib mesylate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.GLEEVEC (imatinib mesylate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.Abbas R., Hug B.A., Leister C., Gaaloul M.E., Chalon S., and Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69:221–227.Abbas R., Hug B.A., Leister C., Gaaloul M.E., Chalon S., and Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69:221–227.Lau Y.Y., Gu W., Lin T., Song D., Yu R., and Scott J.W. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. J Clin Pharmacol. 2016;56:559–566.Lau Y.Y., Gu W., Lin T., Song D., Yu R., and Scott J.W. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. J Clin Pharmacol. 2016;56:559–566.Cho B.C., Kim D.W., Bearz A. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2017;12(Issue 9):1357–1367.Cho B.C., Kim D.W., Bearz A. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2017;12(Issue 9):1357–1367.Cho B.C., Obermannova R., Bearz A. et al. Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study. J Thorac Oncol. 2019 Mar 6;pii: S1556-0864(19)30195-9.Cho B.C., Obermannova R., Bearz A. et al. Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study. J Thorac Oncol. 2019 Mar 6;pii: S1556-0864(19)30195-9.

The authors declare that there are no conflicts of interest present.